TOWA PHARMACEUTICAL CO.,LTD.

Pharmaceutical ・ 4553

Figures below come from this company's annual securities report (有価証券報告書) filed with Japan's Financial Services Agency. Filing a false statement is a criminal offence, which is what makes them worth building on.

Average annual pay
¥6.9m
filing entity, incl. bonuses
vs peers
+¥1.66m
same industry & average age
Average age
35.5 yrs
Average tenure
9.7 yrs
Employees
4,923
consolidated
Market cap
¥192.5bn
J-Quants, ~12-week delay
Working here from 22 to 60est. ¥254m grossindustry norm ¥200m ・ ¥190m after tax and social insurance (75%)
What is left after tax and social insurance? →How much did the 2026 changes move it? →

Corporate Number 4120001157872 (National Tax Agency)

Workforce disclosure

Japan requires listed companies to disclose these three ratios. They are useful but easy to misread — the notes matter.

ItemValue What it does not tell you
Female managers15.6%definition of 'manager' varies by company
Male parental leave66.0%can exceed 100%; says nothing about duration
Gender pay gap (all workers)67.1%women's pay as % of men's; not equal-work comparison
Workplace score (beta)53.7deviation vs all listed, 50 = median
Investment score (beta)50.4deviation vs all listed, 50 = median

Pay history

From past annual securities reports. Reorganisations move this figure even when pay itself does not — the average covers the filing entity only.

Fiscal year endAverage annual pay
2024-03-31¥6.7m
2025-03-31¥6.7m
2026-03-31¥6.9m

Similar companies

Same sector, closest by average pay. A starting point for comparison — not a ranking. Pay differences here are driven as much by average age and by how much of the group sits inside the filing entity as by how well a company pays.

Company Average payAvg ageCode
YUKI GOSEI KOGYO CO.,LTD.¥6.8m44.24531
StemRIM Inc.¥6.9m40.64599
Fuji Pharma Co.,Ltd.¥6.9m43.14554
ノイルイミューン・バイオテック株式会社¥7.1m44.14893
RIBOMIC Inc.¥7.1m41.64591
KOA SHOJI HOLDINGS CO.,LTD.¥7.2m49.09273

Limitations

Source: annual securities report (EDINET, Financial Services Agency of Japan); market data from J-Quants (JPX Market Innovation & Research), ~12-week delay. Compiled independently by Corpus; not provided or endorsed by any government agency. Full detail in Japanese: 東和薬品株式会社.